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Abstract. Proteasome inhibitors have been proven to be effec-
tive anticancer compounds in many tumor models, including 
glioblastoma multiforme (GBM). In this study, we found that 
the proteasome inhibitor Velcade (PS-341/bortezomib) caused 
GBM cell death while simultaneously activating the PI3K/
Akt pathway. Therefore, we sought to investigate if the PI3K 
inhibitor ZSTK474 would enhance the effectiveness of Velcade 
in anticancer therapy. Two GBM cell lines were used to detect 
the effects of Velcade and ZSTK474 alone or in combination 
in vitro. The combination of Velcade and ZSTK474 synergisti-
cally inhibited the proliferation of GBM cell lines. Cell apoptosis 
was increased when exposed to Velcade and ZSTK474 in 
combination as shown by Annexin V analysis. Treatment with 
both drugs led to downregulation of the p-Akt, p-4EBP1 and 
p-mTOR proteins as determined by western blot analysis. The 
anticancer ability of Velcade for glioblastoma multiforme was, 
therefore, enhanced by combination with the PI3K pathway 
inhibitor ZSTK474 in glioblastoma multiforme.
Introduction
The ubiquitin-proteasome pathway is responsible for degrading 
many of the short-lived regulatory proteins which govern cell 
division, growth, activation, signaling and transcription (1). 
Proteasome inhibition is a novel approach to the treatment of 
solid tumors (2). Velcade (PS-341/bortezomib) is a dipeptidyl 
boronic acid inhibitor with high specificity for the proteasome 
and the first proteasome inhibitor evaluated in clinical trials 
(1,3) and approved by the US Food and Drug Administration 
(FDA). We previously found that Velcade had profound effects 
on the growth and apoptosis of GBM cells (4). However, in this 
study, we found that Velcade simultaneously caused an increase 
in P-Akt and left mTOR signaling active in GBM cells.
Glioblastoma multiforme (GBM) is the most common 
primary brain tumor in adults and known as having one of the 
worst prognoses of all cancers. Successful treatment for GBM 
is rare. The median survival for patients is 10-12 months, 
despite aggressive surgical approaches, optimized radiation 
therapy regimens and cytotoxic chemotherapies (5).
The PI3K/Akt pathway in GBM cells is highly active, making 
it an ideal target for cancer therapy (5). Phosphatidylinositol 
3-kinases (PI3Ks) are a class of lipid kinases active in signal trans-
duction that generate phosphatidylinostiol-3,4,5-triphosphate 
(PIP3) by phosphorylating phosphatidylinositol-4,5-bispho-
sphate (6). They are involved in various cellular processes, 
including cell proliferation, adhesion, survival and motility, 
all of which are critical for tumorigenesis (7). Mutation and/or 
amplification of PI3K genes have been reported in many cancer 
cells, including glioblastoma (7,8).
PI3Ks are activated by receptor tyrosine kinases (RTKs). 
GBM cells commonly overexpress the oncogene epidermal 
growth factor receptor (EGFR) and the platelet derived 
growth factor receptor (PDGFR), both of which are the most 
common RTKs (9). Downstream of these receptors, the tumor 
suppressor gene PTEN, is also commonly mutated, further 
promoting the activation of PI3K/AKT pathway (5). Activation 
of PI3K pathway members, such as P-PI3k, P-p7026k and 
P-Akt, has been proven to significantly reduce overall survival 
times when gliomas of all grades are considered (10). Many 
inhibitors of PI3K have been extensively studied, such as 
wortmannin and LY294002. ZSTK474 [2-(2-difluorometh-
ylbenzimidazol-1-y1)-4,6-dimorpholino-1,3,5-triazine] is a 
novel PI3K inhibitor.
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In the present study, the synergistic anti-glioma activity 
of Velcade and ZSTK474 was examined using two GBM 
cell lines. Treatment with both drugs inhibited proliferation 
and increased apoptosis of GBM cells. Detrimental proteins 
for therapy, such as P-Akt, P-4EBP1 and P-mTOR, were 
downregulated in the presence of both drugs. Taken together, 
treatment with the combination of Velcade and ZSTK474 was 
highly effective against GBM and might have a role in the 
future therapy for this aggressive disease.
Materials and methods
Glioma cell lines. Human GBM cell lines U87 and U118 were 
maintained in Dulbecco's modified Eagle's medium (Gibco, 
BRL) with 10% fetal calf serum (Gemini Bio-Products, 
Calabasas, CA, USA). Aliquots were cryopreserved in liquid 
nitrogen, and one aliquot of cells was kept in culture and 
grown to confluence. All cells were incubated at 37˚C in 
5% CO2.
Chemicals. Proteasome inhibitor Velcade, obtained from 
Millennium Pharmaceuticals (Cambridge, MA, USA), was 
reconstituted with normal saline USP/EP at a stock concentra-
tion of 10-4 M and stored at -20˚C. PI3K inhibitor ZSTK474, 
obtained from Selleckchem (Houston, TX, USA), was 
dissolved in DMSO at a stock concentration of 5x10-3 M and 
stored at -20˚C. Fresh dilutions of media were made for each 
experiment.
Cell growth inhibition. Cells were placed into 96-well plates 
at 5.0x103 cells/well and respectively treated with single 
agent alone or their combination for 72 h. Cell proliferation 
was measured by MTT assay. Briefly, 20 µl MTT solution 
(5 mg/ml) was added into each well for the last 4 h. Absorbance 
was measured at 570 nm using a spectrophotometer (Roche 
Molecular Biochemicals, Basel, Switzerland). Cell growth 
was determined in each group and compared with that of the 
untreated cells.
Western blot analysis. Cells were harvested for total cell lysates 
with RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycho-
late, 0.1% SDS, 50 mM Tris-HCl, pH 7.5) containing a mixture 
of protease inhibitors (Roche Diagnostics GmbH, Mannheim, 
Germany) as well as 1 mM NaF and 1 mM NaVO4. Cell lysates 
were centrifuged at 12,000 rpm for 20 min at 4˚C. Supernatant 
was collected, and the protein concentration was measured. 
The lysates (30 µg) were denatured in the sample buffer 
(10% glycerol, 5% B-mercaptoethanol, 2.3% SDS, 62.5 mM 
Tris-HCl, pH 6.8) by boiling and then subjected to 4-15% 
SDS-PAGE followed by electrotransfer to polyvinylidene 
diflouride membrane. The immune complexes were visualized 
with Supersignal West Pico Chemiluminescent Substrate or 
Supersignal west dura extended duration substrate (Pierce, 
Rockford, IL, USA) and normalized by internal control 
(GAPDH). Antibodies against phosphorylated Akt (p-Akt), 
phosphorylated 4E-BP1 (p-4EBP1) and phosphorylated mTOR 
(p-mTOR) were bought from Cell Signaling Technology Inc. 
(MA, USA). Antibodies against cyclin D1, PARP and GAPDH 
were obtained from Santa Cruz Biotechnology Inc. (Santa 
Cruz, CA, USA).
Assessment of apoptosis. Annexin V assays (Annexin V-FITC 
Apoptosis Detection kit; Pharmingen, San Diego, CA, USA) 
were performed according to the manufacturer's instructions. 
Briefly, cells were harvested after exposure to drugs, washed 
twice with PBS, resuspended in 1X binding buffer at a concen-
tration of 1x106 cells/ml, incubated with FITC-conjugated 
Annexin V and PI for 15 min and measured by FACScan 
(Becton-Dickinson).
Results
Velcade activates the PI3K/Akt pathway in GBM cells. The 
effectiveness of Velcade in causing growth arrest and apop-
tosis in GBM cells has been proven (4), but interestingly, we 
found that Velcade could stimulate the cell survival pathway 
PI3K/Akt simultaneously. Using western blot analysis, we 
found that Velcade could induce phosphorylation of Akt, 4E 
binding protein-1 (4EBP1) and mammalian target of rapamycin 
(mTOR) in both GBM cell lines compared to the control. As 
shown in Fig. 1, the amount of P-Akt was increased in cells 
treated with Velcade compared to the control. Furthermore, 
mTOR signaling was activated in the presence of Velcade as 
the amount of P-4EBP1 and P-mTOR was comparable to the 
control.
Synergistic effects of Velcade and ZSTK474 on GBM cell line. 
To study whether the inhibition of the PI3K/Akt signaling 
pathway could enhance the Velcade-induced growth arrest of 
GBM cells, we treated cells with both Velcade and the PI3K 
inhibitor ZSTK474. When adding ZSTK474 (2.5 µM, 24 h), 
the phosphorylation of Akt, 4EBP1 and mTOR was markedly 
decreased in both cell lines (Fig. 1). Cyclin D1, another protein 
central to cell proliferation in the PI3K/Akt pathway, was also 
upregulated in the presence of Velcade alone but downregu-
lated when exposed in both drugs (Fig. 1).
We also examined the effects of Velcade and ZSTK474 
on the proliferation of GBM cells in liquid culture using the 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) assay. Two cell lines were treated with serial dilu-
tions of Velcade or ZSTK474 alone for 72 h. Based on the 
growth inhibition assay, IC50 of Velcade and ZSTK474 was 
calculated to be 40 nM and 7 µM in U87 cells, and 54 nM and 
5 µM in U118 cells (Fig. 2).
To evaluate the combined effects of Velcade and ZSTK474, 
cell lines were individually exposed to both drugs at a fixed 
ratio simultaneously for 72 h spanning the IC50 of each drug. 
The synergistic cytotoxicity was demonstrated by MTT assay 
(Fig. 3A), and the level of synergy at each dose combination was 
further validated by isobole analysis and CIs (Fig. 3B and C). 
The CI values of combined treatment with 10 nM Velcade 
and 1 µM ZSTK474, 20 nM Velcade and 2 µM ZSTK474, 
40 nM Velcade and 4 µM ZSTK474, 80 nM Velcade and 8 µM 
ZSTK474 were 0.696, 0.576, 0.628 and 0.894 in U87 cells, 
and 0.702, 0.585, 0.682 and 0.949 in U118 cells, respectively. 
All of these values were well <1, suggesting high degree of 
synergism between both drugs.
Velcade and ZSTK474 induces more apoptosis on GBM cells 
than either drug alone. In order to investigate whether the 
synergistic cytotoxicity was related to apoptosis, GBM cell 
INTERNATIONAL JOURNAL OF ONCOLOGY  44:  557-562,  2014 559
lines were treated with 100 nM Velcade and 2.5 µM ZSTK474 
alone or their combination simultaneously for 24 h, and stained 
with Annexin V/ PI. Apoptosis was determined by flow cyto-
metry, including early apoptotic cells (Annexin V-positive, 
PI-negative) and late apoptotic cells (Annexin V- and 
PI-positive). The percentage of apoptotic cells in the treatment 
of Velcade and ZSTK474 alone or their combination was 11, 6 
and 20% in U87 cells, and 6, 8 and 27% in U118 cells (Fig. 4), 
Figure 1. Effects of Velcade and ZSTK474 on expression of proteins central to the PI3K/Akt pathway in GBM cell lines. U87 and U118 were cultured for 24 h 
with Velcade (100 nM), ZSTK474 (2.5 µM), or both simultaneously. Lysates were made and subjected to western blot analysis for P-Akt, P-mTOR, P-4EBP1 
and cyclin D1 as well as GAPDH loading control.
Figure 2. Effects of Velcade and ZSTK474 on GBM cell proliferation. Velcade dose-dependently decreased U87 and U118 cell growth after 72 h, with an IC50 
of 40 and 54 nM (A). ZSTK474 dose-dependently inhibited growth with an IC50 of 7 and 5 µM, respectively (B). The cell viability was measured by MTT assay 
and presented as a percent of the control. The IC50 values were calculated using the CalcuSyn software.
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Figure 3. Synergistic effects of Velcade and ZSTK474 on GBM cell lines. Combination of Velcade and ZSTK474 at a fixed ratio synergistically inhibited cell 
growth (A). Isobologram analysis of all of the combination treatment groups fell below the synergistic threshold (B). Combination index (CI) values extrapo-
lated from isobole analysis were <1 (C), altogether strongly indicating the synergistic effects of Velcade and ZSTK474 on GBM cells.
Figure 4. Apoptotic analysis of GBM cell lines treated with Velcade and ZSTK474. GBM cell lines were cultured for 24 h with 100 nM Velcade, 2.5 µM 
ZSTK474, or both simultaneously. Apoptosis was assessed by Annexin V (FL-1) and PI (FL-3) staining and FACS analysis. Three experiments were carried 
out for each cell line and the results were similar. Representative experiments are shown.
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indicating that more apoptosis was caused in the presence of 
both drugs.
Immunoblotting analysis of the apoptotic-related protein 
poly(ADP-ribose) polymerase (PARP) showed that the 
C-terminal 85 kDa PARP apoptotic fragment was generated 
in each cell line when treated with both Velcade and ZSTK474 
(Fig. 5).
Discussion
Proteasome inhibitors are emerging as a promising class of 
agents in the treatment of cancers (1,2). In particular, the 
proteasome inhibitor Velcade (PS-341/bortezomib) has been 
in clinical trials for many years for cancer patients with 
advanced diseases, mostly multiple myeloma and mantle cell 
lymphoma (3,11). Based on positive preclinical and clinical 
studies, Velcade was approved by the US Food and Drug 
Administration (FDA) for clinical use for multiple myeloma 
treatment in 2008.
We have previously proven the effectiveness of Velcade in 
causing growth arrest and apoptosis in GBM cells (4). However, 
we recently discovered that in GBM Velcade also activated the 
PI3K/Akt pathway, which is known to increase tumorigenesis 
and is involved in cell proliferation (12). Through western blot 
analysis, we found that Velcade caused upregulation of P-Akt 
and left the mTOR signaling still active (Fig. 1).
Thus, we assumed that blocking the PI3K/Akt pathway 
might lead to the enhancement of the anticancer ability 
of Velcade. In order to deactivate the PI3K/Akt pathway, 
we used the novel PI3K inhibitor ZSTK474 in conjunc-
tion with Velcade. ZSTK474 has previously been proven to 
suppress tumor growth in GBM (13,14). With the presence 
of ZSTK474, P-Akt, P-4EBP1 and P-mTOR were down-
regulated. Cyclin D1 was also upregulated in the presence 
of Velcade alone but downregulated with the combination of 
both drugs (Fig. 1).
In order to prove the synergistic effects of Velcade and 
ZSTK474, cell proliferation was examined by MTT assay. 
As the CI values of each dose combination were <1 (Fig. 3C), 
synergism was observed between the two drugs. Annexin V 
assays were also performed to study the induction of cell 
apoptosis, and an increase in apoptosis was observed in the 
presence of both drugs.
In conclusions, we demonstrated that Velcade and ZSTK474 
was a synergistic drug combination that had profound effects 
on GBM cells. This was accompanied by increased apoptosis 
and decreased activation of many proteins central to the PI3K/
Akt pathway. These findings suggested that combination treat-
ment of Velcade and ZSTK474 might have a niche in the future 
therapy for glioblastomas.
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